Knott David M Jr — 13F Holdings & Portfolio
CIK 1892770 · latest 13F-HR filed 2026-11-12
Knott David M Jr manages $182.8M in 13F-reported U.S. long-equity assets across 82 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are GOOG (17.00%), APO (14.28%), IOVA (9.44%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 8 new positions and exited 12; 22 existing positions rose in reported value and 30 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-12
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 66.7%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Iovance Biotherapeutics, Inc.$10.6M +159.4%
- Cybin Inc$2.1M +85.9%
- Xeris Biopharma Holdings, Inc.$1.2M +14.2%
- CareDx, Inc.$1.1M +270.9%
- Enliven Therapeutics, Inc.$1.0M +322.2%
Top Trims
- Protagonist Therapeutics, Inc-$3.1M -40.3%
- Agios Pharmaceutical, Inc.-$1.9M -53.8%
- Alkermes PLC-$1.7M -27.3%
- Syndax Pharmaceutical, Inc.-$1.5M -15.8%
- Relmada Therapeutics, Inc.-$1.3M -42.0%
New Positions
- Oruka Therapeutics, Inc.$916.2K
- Collegium Pharmaceutical, Inc.$851.0K
- Dyne Therapeutics, Inc.$837.7K
- DuPont de Nemours, Inc.$489.3K
- Edgewise Therapeutics, Inc.$426.4K
Exited Positions
- Catalyst Pharmaceuticals, Inc.$3.6M
- AtriCure, Inc.$1.4M
- Ardelyx, Inc.$1.3M
- Ultragenyx Pharmaceutical Inc.$1.3M
- Vera Therapeutics, Inc.$1.1M
Knott David M Jr Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Alphabet Inc-Cl C | GOOG | 02079K107 | $31.1M | 17.00% | 91,200 | SH |
| 2 | Apollo Global Management, Inc. | APO | 03769M106 | $26.1M | 14.28% | 225,000 | SH |
| 3 | Iovance Biotherapeutics, Inc. | IOVA | 462260100 | $17.3M | 9.44% | 1,165,000 | SH |
| 4 | Xeris Biopharma Holdings, Inc. | XERS | 98422E103 | $9.6M | 5.24% | 1,002,900 | SH |
| 5 | Syndax Pharmaceutical, Inc. | SNDX | 87164F105 | $8.1M | 4.40% | 428,294 | SH |
| 6 | Travere Therapeutics, Inc. | TVTX | 89422G107 | $7.7M | 4.19% | 129,967 | SH |
| 7 | Bridgebio Pharma, Inc. | BBIO | 10806X102 | $6.6M | 3.60% | 100,000 | SH |
| 8 | JPMorgan Chase & Co. | JPM | 46625H100 | $5.8M | 3.15% | 17,409 | SH |
| 9 | LPL Financial Holdings Inc. | LPLA | 52012V100 | $5.0M | 2.76% | 16,500 | SH |
| 10 | Janus Henderson AAA CLO ETF | JAAA | 47103U845 | $4.7M | 2.58% | 93,528 | SH |
| 11 | Alkermes PLC | ALKS | G01767105 | $4.6M | 2.54% | 114,459 | SH |
| 12 | Protagonist Therapeutics, Inc | PTGX | 74366E102 | $4.6M | 2.52% | 32,723 | SH |
| 13 | Cybin Inc | HELP | 23256X407 | $4.5M | 2.49% | 370,000 | SH |
| 14 | Cogent Biosciences Inc. | COGT | 19240Q201 | $4.4M | 2.38% | 136,081 | SH |
| 15 | Viridian Therapeutics, Inc. | VRDN | 92790C104 | $3.9M | 2.15% | 191,000 | SH |
| 16 | TG Therapeutics, Inc. | TGTX | 88322Q108 | $3.3M | 1.83% | 59,839 | SH |
| 17 | Arcus Biosciences, Inc. | RCUS | 03969F109 | $2.6M | 1.42% | 100,241 | SH |
| 18 | Madrigal Pharmaaceuticals, Inc. | MDGL | 558868105 | $1.8M | 0.99% | 3,600 | SH |
| 19 | Relmada Therapeutics, Inc. | RLMD | 75955J402 | $1.8M | 0.99% | 480,000 | SH |
| 20 | SPDR S&P Biotech ETF | XBI | 78464A870 | $1.7M | 0.95% | 11,000 | SH |
| 21 | AllianceBernstein Holding L.P. | AB | 01881G106 | $1.7M | 0.92% | 48,000 | SH |
| 22 | Agios Pharmaceutical, Inc. | AGIO | 00847X104 | $1.6M | 0.89% | 49,058 | SH |
| 23 | Orchestra Biomed Holdings, Inc. | OBIO | 68572M106 | $1.6M | 0.86% | 253,651 | SH |
| 24 | Cullinan Therapeutics, Inc. | CGEM | 230031106 | $1.5M | 0.80% | 95,369 | SH |
| 25 | CareDx, Inc. | CDNA | 14167L103 | $1.4M | 0.79% | 22,165 | SH |
| 26 | Enliven Therapeutics, Inc. | ELVN | 29337E102 | $1.3M | 0.72% | 28,904 | SH |
| 27 | Spruce Biosciences, Inc. | SPRB | 85209E208 | $1.3M | 0.69% | 26,085 | SH |
| 28 | Eldgridge BBB-B | CLOZ | 81752T528 | $1.3M | 0.69% | 47,807 | SH |
| 29 | DocGo, Inc. | DCGO | 256086109 | $1.1M | 0.58% | 2,670,850 | SH |
| 30 | Pfizer Inc. | PFE | 717081103 | $922.3K | 0.50% | 32,337 | SH |
| 31 | Oruka Therapeutics, Inc. | ORKA | 687604108 | $916.2K | 0.50% | 11,000 | SH |
| 32 | Collegium Pharmaceutical, Inc. | COLL | 19459J104 | $851.0K | 0.47% | 39,000 | SH |
| 33 | Dyne Therapeutics, Inc. | DYN | 26818M108 | $837.7K | 0.46% | 52,000 | SH |
| 34 | Apple Inc. | AAPL | 037833100 | $830.6K | 0.45% | 2,494 | SH |
| 35 | Microsoft Corporation | MSFT | 594918104 | $820.6K | 0.45% | 1,600 | SH |
| 36 | Rezolute, Inc. | RZLT | 76200L309 | $660.9K | 0.36% | 159,638 | SH |
| 37 | Canadian Natural Resources Limited | CNQ | 136385101 | $655.1K | 0.36% | 13,918 | SH |
| 38 | LB Pharmaceuticals, Inc. | LBRX | 50180M108 | $655.0K | 0.36% | 17,065 | SH |
| 39 | Johnson & Johnson | JNJ | 478160104 | $529.5K | 0.29% | 2,000 | SH |
| 40 | iShares Biotechnology ETF | IBB | 464287556 | $526.3K | 0.29% | 2,500 | SH |
| 41 | Solid Bioscience Inc. | SLDB | 83422E204 | $514.3K | 0.28% | 71,129 | SH |
| 42 | DuPont de Nemours, Inc. | DD | 26614N102 | $489.3K | 0.27% | 3,767 | SH |
| 43 | International Business Machines | IBM | 459200101 | $471.1K | 0.26% | 2,142 | SH |
| 44 | Connect Biopharma Holdings Limited | CNTB | G23549101 | $461.9K | 0.25% | 419,866 | SH |
| 45 | Biogen Inc. | BIIB | 09062X103 | $451.8K | 0.25% | 2,000 | SH |
| 46 | Edgewise Therapeutics, Inc. | EWTX | 28036F105 | $426.4K | 0.23% | 10,502 | SH |
| 47 | Pelthos Therapeutics, Inc. | PTHS | 171126204 | $370.7K | 0.20% | 17,644 | SH |
| 48 | Nvidia Corp | NVDA | 67066G104 | $292.3K | 0.16% | 1,280 | SH |
| 49 | Ryman Hospitality Properties, Inc. | RHP | 78377T107 | $286.9K | 0.16% | 2,400 | SH |
| 50 | Insmed Incorporated | INSM | 457669307 | $257.2K | 0.14% | 2,253 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | $182.8M | 82 | 0001104659-26-125757 |
| 2026-06-30 | 2026-08-12 | $189.2M | 86 | 0001104659-26-094536 |
| 2026-03-31 | 2026-05-14 | $168.0M | 88 | 0001104659-26-060750 |
| 2025-12-31 | 2026-02-12 | $215.9M | 91 | 0001104659-26-014058 |
| 2025-09-30 | 2025-11-12 | $248.0M | 92 | 0001104659-25-110124 |
485 UNDERHILL BOULEVARD, SUITE 205
SYOSSET, NY 11791